CardiologyPublished: May 2026·Updated: May 2026·8 min read

AF Burden: When Ablation Outperforms Antiarrhythmic Drugs

<strong>Atrial fibrillation burden</strong> — the proportion of time a patient actually spends in AF — is emerging as one of cardiology's most clinically meaningful metrics. Catheter ablation in Singapore reduces this burden far more effectively than any antiarrhythmic drug currently available, and a landmark 2024 European Heart Journal review (Becher et al., EHJ 2024;45:2824) has crystallised why this matters: how much AF a patient carries directly predicts their risk of stroke, heart failure, and death. The implication for treatment decisions is significant — and the evidence from multiple landmark trials now makes the case for ablation compellingly.

Dr. Peter Chang

Triple Board-Certified Cardiologist & Vascular Specialist

What Is AF Burden and Why Does It Now Matter?

Traditionally, a patient either had atrial fibrillation or they didn't. That binary view, while clinically convenient, has always felt inadequate — intuitively, someone spending 2% of their day in AF seems meaningfully different from someone spending 80%. AF burden, defined as the percentage of time spent in AF over a monitored period, gives clinicians a way to quantify that difference precisely.

A landmark review published in the European Heart Journal (Becher et al., EHJ 2024;45:2824) formally established AF burden as a new outcome predictor and therapeutic target. The review synthesised evidence from continuous device monitoring across tens of thousands of patients and concluded that AF burden independently correlates with stroke risk, heart failure incidence, cognitive decline, and all-cause mortality — outcomes that a simple AF diagnosis code cannot distinguish. In Singapore, where implantable cardiac monitors and extended Holter monitoring are increasingly accessible, this changes how we stratify and counsel our AF patients.

AF burden = percentage of time in AF over a monitored period
Measured via implantable cardiac monitors (ICMs), pacemakers, extended Holter monitors, or validated wearables
Short, infrequent device-detected episodes carry substantially lower risk than sustained or frequent AF
The 2024 ESC AF Guidelines now incorporate burden into risk stratification frameworks

How AF Burden Predicts Stroke, Heart Failure, and Mortality

The relationship between AF burden and stroke risk is dose-dependent — a finding with direct implications for both anticoagulation and ablation decisions. The KP-RHYTHM study found that paroxysmal AF patients in the highest burden tertile (above 11.4%) had more than a 3-fold higher rate of thromboembolism compared with lower-burden groups, even after adjusting for CHA2DS2-VASc scores, suggesting burden captures prognostic information that conventional risk scores alone miss.

The relationship extends beyond stroke. Analysis of 39,710 continuously monitored patients revealed a dose-dependent association: each 10% increase in AF burden was associated with a 9% increased risk of new-onset heart failure and, in those with established heart failure, a 6% increase in mortality. The CASTLE-AF substudy added a pivotal data point: patients whose AF burden fell below 50% at six months post-ablation experienced a 67% reduction in the primary composite cardiovascular outcome and a 77% reduction in all-cause mortality.

Highest AF burden tertile (>11.4%) → >3-fold thromboembolism risk (KP-RHYTHM study)
Each 10% increase in AF burden → 9% increased new-onset heart failure risk
AF burden <50% post-ablation → 67% reduction in composite cardiovascular outcome (CASTLE-AF)
Meaningful quality-of-life improvement with every 30% relative burden reduction (CIRCA-DOSE trial)

Does Ablation Reduce AF Burden Better Than Medication?

The short answer, supported by multiple independent trials, is yes — and the magnitude is larger than many patients expect. In the landmark CABANA trial, AF burden at 12 months averaged 7% in the catheter ablation arm versus 18% in the drug therapy arm. At five years, those figures were 17% versus 26%. Ablation maintained a sustained burden advantage across the entire follow-up period.

Quality-of-life scores (AFEQT) were consistently and significantly higher in the ablation arm at every follow-up point out to 60 months. The CIRCA-DOSE substudy translates what burden reduction means for daily life: AF episodes exceeding one hour were associated with a 3-fold increase in emergency department visits and a 5-fold increase in hospitalisations. Reducing burden from high to low is not merely a number improving on a monitor — it means fewer unplanned hospital admissions in Singapore and a meaningfully better quality of life.

ATTEST Trial: Ablation Delays Progression to Persistent AF

The ATTEST trial addressed a specific and clinically urgent question: does catheter ablation delay progression from paroxysmal to persistent AF more effectively than antiarrhythmic drugs? The result was unambiguous. In this multicentre, randomised, controlled trial across 29 hospitals in 13 countries, 255 patients with paroxysmal atrial fibrillation were assigned to radiofrequency ablation or guideline-directed antiarrhythmic therapy.

At three years, the rate of progression to persistent AF or atrial tachycardia was 2.4% in the ablation group versus 17.5% in the antiarrhythmic drug group (hazard ratio 0.114, p = 0.0009) — meaning ablation-treated patients were approximately 10 times less likely to progress to persistent AF. The superiority of ablation was evident at the one-year mark and sustained through three years. One sobering finding: patients older than 65 were four times more likely to progress regardless of treatment, underlining that earlier intervention yields better returns.

ATTEST: progression to persistent AF — 2.4% ablation vs 17.5% antiarrhythmic drugs at 3 years (p = 0.0009)
Ablation patients were approximately 10 times less likely to develop persistent AF (HR = 0.114)
Benefit was evident at 1 year and sustained through 3 years of follow-up
Patients over 65 were 4 times more likely to progress regardless of treatment — early intervention is key

EAST-AFNET 4: The Case for Early Rhythm Control

The EAST-AFNET 4 trial established a principle now reshaping AF management internationally: early rhythm control — initiated within one year of diagnosis — significantly reduces adverse cardiovascular outcomes. Rhythm control therapy comprising antiarrhythmic drugs and catheter ablation reduced the composite outcome of stroke, cardiovascular death, and hospitalisation for heart failure or acute coronary syndrome from 4.4% to 2.9% (p = 0.03).

Crucially, this benefit was not observed in patients where AF had been present for more than a year before intervention. This confirms that AF burden reduction achieved before structural remodelling of the atria becomes entrenched carries the greatest prognostic impact. For patients in Singapore newly diagnosed with paroxysmal AF, this argues compellingly for a proactive and early discussion about ablation — rather than deferring until antiarrhythmic drugs have failed over several years of ongoing atrial damage.

Measuring AF Burden in Singapore: What to Expect

Accurately quantifying atrial fibrillation burden in Singapore requires continuous or extended rhythm monitoring — a standard 12-lead ECG captures only seconds and will miss paroxysmal episodes entirely. At Paragon Medical Centre on Orchard Road, we use a tiered approach matched to the clinical picture.

A 24-hour Holter monitor is appropriate when symptoms occur daily. Extended Holters of 7 to 14 days better capture paroxysmal AF with less frequent episodes. For patients with very infrequent symptoms, those with cryptogenic stroke, or those requiring post-ablation surveillance, an implantable cardiac monitor (ICM) — subcutaneous, approximately the size of a USB drive — records continuously for up to three years and transmits data remotely. Validated smartwatch ECG features increasingly supplement clinical monitoring between visits. The monitoring strategy is tailored individually and discussed at the initial consultation.

Who Should Consider AF Ablation in Singapore?

The 2024 ESC Guidelines and accumulated trial evidence support catheter ablation across several well-defined patient groups. Patients with symptomatic paroxysmal or persistent atrial fibrillation ablation who have failed or wish to avoid long-term antiarrhythmic therapy remain the primary indication. ATTEST and EAST-AFNET 4 now support earlier consideration, particularly for younger patients with high burden or at risk of progression.

Patients with AF and concurrent heart failure derive particular benefit — the CASTLE-AF mortality data in this cohort is among the most compelling in the ablation literature. At our Singapore clinic, every patient undergoes individual assessment: AF burden by monitoring, left atrial size, symptom profile, comorbidity burden, and their own preference for procedural versus pharmacological management. The evidence tilts increasingly towards earlier ablation for those who qualify.

Symptomatic paroxysmal or persistent AF after failed antiarrhythmic therapy (Class I, ESC 2024)
Paroxysmal AF with high burden seeking to avoid long-term antiarrhythmic medication (Class IIa)
AF with concurrent heart failure — strongest mortality reduction data (CASTLE-AF)
Newly diagnosed paroxysmal AF within 1 year of diagnosis for early rhythm control (EAST-AFNET 4)
Documented progression risk: age >65, enlarged left atrium, high Holter burden

Frequently Asked Questions

Common Questions About AF Burden

What is AF burden and how is it measured?

AF burden is the percentage of time a patient spends in atrial fibrillation over a monitored period. It is measured using continuous rhythm monitors — Holter monitors (24 hours to 14 days), implantable cardiac monitors (up to 3 years), or validated wearable devices. A 2024 European Heart Journal review confirmed that AF burden independently predicts stroke, heart failure, and mortality, making it a key target for treatment decisions alongside conventional risk scores.

Is catheter ablation better than medication for atrial fibrillation?

For reducing AF burden and preventing disease progression, yes — consistently and across multiple trials. The CABANA trial showed AF burden of 7% versus 18% (ablation vs drugs) at 12 months. The ATTEST trial found only 2.4% of ablation patients progressed to persistent AF versus 17.5% on antiarrhythmic drugs at 3 years. Quality-of-life scores were better in the ablation group at every timepoint over 5 years of follow-up.

Can ablation prevent paroxysmal AF becoming persistent in Singapore?

The ATTEST trial answers this directly: ablation-treated patients were approximately 10 times less likely to progress to persistent AF compared with those on antiarrhythmic drugs — 2.4% versus 17.5% at 3 years. Early intervention appears to carry the greatest benefit (EAST-AFNET 4: best outcomes when rhythm control starts within 1 year of diagnosis). At Paragon Medical Centre, we discuss this data with every eligible patient at first presentation.

Does reducing AF burden lower stroke risk?

The relationship is dose-dependent. The KP-RHYTHM study found that the highest-burden paroxysmal AF patients had more than 3 times the thromboembolism risk of lower-burden patients, even after adjusting for standard risk scores. The Eur Heart J 2024 review by Becher et al. concluded that AF burden should be incorporated into future anticoagulation decisions alongside CHA2DS2-VASc scoring, though firm guideline thresholds are still being established.

What is the success rate of AF ablation in Singapore?

For paroxysmal AF, single-procedure freedom from AF at 12 months is typically 70-80%, with higher rates after repeat procedures. The more clinically meaningful measure is burden reduction: the CABANA trial showed a 50% overall reduction in AF recurrence, with sustained quality-of-life benefit even in patients with some AF return. Success depends on AF duration, left atrial size, and how early intervention occurs.